Impact That Matters

Learn about HNF’s Research Initiatives

Research programs that can change people’s lives

We prioritize research programs that will change people’s lives by partnering with innovative researchers and industry leaders.

We ONLY support projects that have potential to have an impact on human health.



HNF developed the Therapeutic Research in Accelerated Discovery (TRIAD) as a patient-led collaborative network with academia, government, and industry to develop treatments for CMT. Currently TRIAD involves many groups that span the drug discovery, drug development, and diagnostics continuum.

Our core philosophy mandates that we collaborate with our patient community and strategic partners compassionately, honestly and with integrity. The patient always comes first and drives our patient support and research efforts.

CMT & Pediatrics

HNF has a dedicated CMT & Pediatric initiative to support the development of clinical trials.  


As part of TRIAD, in 2013, the Global Registry for Inherited Neuropathies (GRIN) was developed as an extension to conduct patient-focused research & development for treatments and cures. The patient voice is at the forefront of all we do. By Incorporating the patient voice from the very beginning, our research programs have the greatest potential for success.

HNF funds research with one goal in mind, advancing to clinical trials. Partnerships vary depending on research goals, milestones met, preclinical or clinical development and the strategic alliance agreement. 

Learn more on this topic

Latest News and Related Blog Posts

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Hot off the press

Some recent papers on Charcot-Marie-Tooth (CMT) disease go to show that we are steadily and impressively peeling back the complexity of the biology even though it is a relatively common rare disease with several thousand publications on it.